Improving clinical trial accrual by streamlining the referral process

OBJECTIVE Poor accrual rates impede clinical trial efficiency and significantly contribute to development costs for new interventions. Many providers recognize investigational treatments are their patients' best opportunities for improvement, but operational clinical burdens impede providers' awareness of, and ability to leverage, such opportunities. We aimed to develop a new workflow for non-intrusively apprising providers of trial opportunities for their patients and enabling providers to efficiently refer potential trial candidates to study teams for preliminary eligibility review. MATERIALS AND METHODS We developed a small information system to monitor institutional systems, identify patients potentially eligible for ongoing clinical trials, and give providers a non-intrusive, one-click method to refer such patients to study teams for preliminary eligibility vetting. RESULTS In 18 months of pilot experience, providers invited study teams to vet 11% of 1844 patients found potentially eligible for 38 trials registered with the system. Seventy-nine patients were conservatively estimated to be accrued. Accrual rates were boosted for several trials. Results of a survey indicated most users were satisfied with the system. DISCUSSION Providers' time constraints impede their pursuit of investigational opportunities for their patients. In pilot experience, our novel approach to facilitating such pursuits yielded improved accrual, benefiting trials and presumably patients, too. Our approach may bear particular fruit for cross-disciplinary referrals for screening. CONCLUSION Systems for assisting providers in making investigational opportunities available to their patients may benefit from careful attention to provider workflow and time constraints. Our system might further benefit from improved patient/trial matching and shorter messages.

[1]  Michelle A. Mathiason,et al.  Clinical trial accrual among new cancer patients at a community‐based cancer center , 2006, Cancer.

[2]  B. Munos Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[3]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[4]  Peter J. Embi,et al.  Development of an Electronic Health Record-based Clinical Trial Alert System to Enhance Recruitment at the Point of Care , 2005, AMIA.

[5]  Jon D. Miller,et al.  Public attitudes toward participation in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Prescott,et al.  Barriers to participation in randomised controlled trials: a systematic review. , 1999, Journal of clinical epidemiology.

[7]  P. LoRusso,et al.  Accrual to breast cancer clinical trials at a university-affiliated hospital in metropolitan Detroit. , 1999, American journal of clinical oncology.

[8]  M. Christian,et al.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Gafni,et al.  Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L J Mahoney,et al.  Reasons for non‐entry in randomized clinical trials for breast cancer: A single institutional study , 1992, Journal of surgical oncology.

[11]  L. Beckett,et al.  An Evaluation of Barriers to Accrual in the Era of Legislation Requiring Insurance Coverage of Cancer Clinical Trial Costs in California , 2004, Cancer journal.

[12]  A. Towse,et al.  The R&D Cost of a New Medicine , 2012 .

[13]  Kevin B. Weiss,et al.  Managing Complexity in Chronic Care: An overview of the VA State-of-the-Art (SOTA) Conference , 2007, Journal of General Internal Medicine.

[14]  Peter J. Embi,et al.  Physicians' perceptions of an electronic health record-based clinical trial alert approach to subject recruitment: A survey , 2008, BMC Medical Informatics Decis. Mak..

[15]  J. Concato,et al.  Vector Model of Complexity , 2008, Journal of general internal medicine.

[16]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.

[17]  D. Hunninghake,et al.  Recruitment for controlled clinical trials: literature summary and annotated bibliography. , 1997, Controlled clinical trials.

[18]  Lawrence B. Afrin,et al.  Leveraging of Open EMR Architecture for Clinical Trial Accrual , 2003, AMIA.

[19]  E. Fisher,et al.  The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. , 1992, American journal of public health.

[20]  Jeroan J. Allison,et al.  Patient Complexity: More Than Comorbidity. The Vector Model of Complexity , 2007, Journal of General Internal Medicine.

[21]  L. Dyrbye,et al.  Physician burnout: a potential threat to successful health care reform. , 2011, JAMA.

[22]  E. DeLong,et al.  Discordance of Databases Designed for Claims Payment versus Clinical Information Systems: Implications for Outcomes Research , 1993, Annals of Internal Medicine.

[23]  R. Kravitz,et al.  Frequent overcrowding in U.S. emergency departments. , 2001, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[24]  Rosaline Joseph,et al.  Viewpoints and concerns of a clinical trial participant , 1994, Cancer.

[25]  I. Morrison The Future of Physicians' Time , 2000, Annals of Internal Medicine.

[26]  H. Quan,et al.  Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. , 2008, Health services research.

[27]  Moon S. Chen,et al.  Overcoming barriers to cancer clinical trial accrual , 2008, Cancer.

[28]  E. Mansour,et al.  Barriers to clinical trials: Part III: Knowledge and attitudes of health care providers , 1994, Cancer.

[29]  R. Yancik,et al.  Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log. , 1987, Cancer treatment reports.

[30]  Van V. Brantner,et al.  Estimating the Costs of New Drug Development: Is it really $802m? , 2005 .

[31]  D. Gandara,et al.  Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Joel Lexchin,et al.  The cost of drug development: a systematic review. , 2011, Health policy.

[33]  J. DiMasi,et al.  Drug development costs when financial risk is measured using the Fama-French three-factor model. , 2009, Health economics.

[34]  Clement J. McDonald,et al.  What can natural language processing do for clinical decision support? , 2009, J. Biomed. Informatics.

[35]  P M Ellis,et al.  Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Shiraz I Mishra,et al.  Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. , 2006, Cancer detection and prevention.